Abarceo Pharma
Founded 2017 · 10 employees on LinkedIn · 2 known investors
Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.
Founders & leadership
Abarceo Pharma was founded in 2017 by Claes Wollheim and Albert Salehi.
CW
Claes WollheiminFounder (Prof., MD)
AS
Albert SalehiFounder (Associate Prof.)
Investors · 2
In the news
Frequently asked questions
- What does Abarceo Pharma do?
- Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.
- Who founded Abarceo Pharma?
- Abarceo Pharma was founded by Claes Wollheim, Albert Salehi in 2017.
- Who are Abarceo Pharma's investors?
- Abarceo Pharma's investors include LU Innovation, Almi Invest.